Loading clinical trials...
Loading clinical trials...
A Multicenter Open-Label Extension (OLE) Study To Assess The Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 MG
The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Jedidiah Clinical Research
Tampa, Florida, United States
L-MARC Research Center
Louisville, Kentucky, United States
Sentral Clinical Research Services
Cincinnati, Ohio, United States
Start Date
February 3, 2017
Primary Completion Date
November 5, 2019
Completion Date
November 5, 2019
Last Updated
March 1, 2021
1,462
ACTUAL participants
bempedoic acid
DRUG
Lead Sponsor
Esperion Therapeutics, Inc.
NCT07058077
NCT06813911
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06295679